Status:
COMPLETED
Pregabalin Open-Label Extension Trial in Patients With Partial Seizures
Lead Sponsor:
Pfizer
Conditions:
Epilepsies, Partial
Epilepsy, Complex Partial
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The primary purpose of the protocol is to evaluate the long-term safety of pregabalin in patients with partial seizures.
Eligibility Criteria
Inclusion
- Patients must have met the inclusion criteria for Study 1008-157, have received double-blind study medication, and wish to receive open-label pregabalin
- Have the diagnosis of epilepsy with partial seizures and have a minimum of 4 partial seizures during the 6 weeks prior to screening
- Be currently taking 1 to 3 AEDs.
Exclusion
- Have a treatable cause of seizures
- Experienced a serious adverse event during Study 1008-157 which was determined to be possibly related to study medication
Key Trial Info
Start Date :
September 1 2001
Trial Type :
INTERVENTIONAL
End Date :
February 1 2006
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT00143143
Start Date
September 1 2001
End Date
February 1 2006
Last Update
July 24 2006
Active Locations (47)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Innsbruck, Austria, A6020
2
Pfizer Investigational Site
Mauer bei Amstetten, Austria, 3362
3
Pfizer Investigational Site
Sankt Pölten, Austria, A3100
4
Pfizer Investigational Site
Vienna, Austria, 1090